Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHERGAIN-2
NCT04733118Phase 2Active, not recruiting
- Sponsor
- MEDSIR
- Start
- Aug 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Drug Delivery Systems, Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
A Phase 2 trial of trastuzumab + pertuzumab, trastuzumab emtansine in breast cancer, sponsored by MEDSIR. Started Aug 2021; status: active, not recruiting.
02
Drugs
trastuzumab + pertuzumabtrastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04733118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04733118.